Can I stop my blood pressure medication on Ozempic or Wegovy?

Sometimes — but only with your clinician. GLP-1 weight loss lowers blood pressure, and in the STEP 1 and 4 trials semaglutide produced net reductions in antihypertensive medication use. That means some people can step down BP meds as they lose weight. It must be a monitored, gradual taper, because stopping certain drugs abruptly can cause rebound spikes.

How much does a GLP-1 lower blood pressure?

On average, meaningfully: tirzepatide lowered systolic pressure by roughly 4–6 mmHg across doses in meta-analysis, and semaglutide significantly reduced systolic and diastolic pressure in STEP 1 and 4. Individuals who lose a lot of weight can see larger drops — which is why some end up over-medicated on their old BP regimen.

I feel dizzy on my BP meds since starting a GLP-1 — why?

As your own blood pressure falls with weight loss, your unchanged BP medications can push it too low, causing lightheadedness (especially on standing), fatigue, or near-fainting. Check your blood pressure and contact your clinician — your medication may need to be reduced.

Do I need to hold my BP meds when I'm nauseated on a GLP-1?

Possibly. Diuretics, ACE inhibitors, and ARBs interact badly with dehydration from severe GLP-1 nausea, vomiting, or diarrhea (risking kidney injury and low blood pressure). Ask your clinician for 'sick-day' rules — a plan for temporarily holding these drugs when you can't keep fluids down.

Coming Off Blood-Pressure Meds on a GLP-1

↓ BP + ↓ medsIn STEP 1 & 4, semaglutide lowered blood pressure AND produced net reductions in antihypertensive medication use (Kosiborod 2023)

As you lose weight on a GLP-1 (Ozempic, Wegovy) or GLP-1/GIP (Mounjaro, Zepbound), your blood pressure usually falls — and for some people that means existing blood-pressure medications become too strong, opening the door to deprescribing (reducing or stopping a BP drug). This isn't speculation: in the STEP 1 and STEP 4 trials, semaglutide lowered systolic and diastolic blood pressure and produced net reductions in antihypertensive medication use versus placebo (Kosiborod 2023 ^[1]); tirzepatide lowered systolic pressure by roughly 4–6 mmHg across doses in meta-analysis (Kanbay 2023 ^[2]). The critical caveat: deprescribing is a clinician-guided process — stopping BP meds on your own, or missing developing low blood pressure, is how people get hurt. Here's what the evidence shows and how it's done safely.

The honest summary

GLP-1 weight loss lowers blood pressure. Both semaglutide (STEP 1/4, Kosiborod 2023^[1]) and tirzepatide (Kanbay 2023^[2], SBP roughly -4.2 to -5.8 mmHg by dose) significantly reduce blood pressure.
Medication use actually went down. STEP 1 and 4 showed net reductions in antihypertensive (and lipid-lowering) medication use with semaglutide versus placebo — real-world evidence that some people need less BP medication as they lose weight.
Deprescribing is a clinician decision, not a DIY one. Reducing or stopping a BP drug requires monitoring (home readings, follow-up) and the right order of withdrawal — it is individualized.
Watch for symptoms of over-treatment. As your own BP falls, unchanged BP meds can push it too low — dizziness, lightheadedness on standing, fatigue, or fainting are signals to check readings and call your clinician.
Some BP meds need care during GI side effects. Diuretics, ACE inhibitors, and ARBs interact with dehydration from GLP-1 nausea/vomiting — ask about “sick-day” rules.

What the trials show

Kosiborod 2023^[1] analyzed cardiometabolic risk factors in the STEP 1 and STEP 4 trials of once-weekly semaglutide 2.4 mg in people with overweight or obesity without diabetes. Reductions in systolic and diastolic blood pressure (alongside waist circumference, fasting glucose, fasting insulin, and lipids) were significantly greater with semaglutide than placebo. The standout for this topic: the analysis reported net reductions in antihypertensive and lipid-lowering medication use with semaglutide versus placebo — i.e., on balance, more people were able to step down BP medication. For tirzepatide, Kanbay 2023^[2] (meta-analysis of 7 RCTs) quantified systolic reductions of about -4.2 mmHg at 5 mg up to -5.8 mmHg at 15 mg, dose-dependent. These are meaningful averages — and individuals who lose substantial weight can see larger drops.

Why blood pressure falls

Excess weight raises blood pressure through several routes — increased blood volume, sympathetic-nervous-system activity, insulin resistance, and sleep apnea. GLP-1 weight loss unwinds several of these at once. There may be modest direct vascular effects too, but the weight loss does most of the work, which is why the BP drop tends to track with how much weight you lose.

Deprescribing — the safe way to do it

“Deprescribing” means intentionally reducing or stopping a medication that's no longer needed (or now too strong). It is a legitimate, often desirable goal as your weight and BP improve — fewer pills, fewer side effects, lower cost. But it has to be done deliberately:

Don't stop on your own. Abruptly stopping some BP drugs (notably beta-blockers and clonidine) can cause rebound spikes. The order and pace of withdrawal matter.
Monitor at home. Bring home blood-pressure readings to your clinician — trends guide whether and how to taper.
Expect a stepwise taper. Clinicians typically reduce one agent at a time, recheck, and adjust — especially as weight loss continues and BP keeps drifting down.
Flag low-BP symptoms early. Lightheadedness (especially standing up), unusual fatigue, or near-fainting can mean your meds are now too strong for your lower weight.
Mind the sick-day rules. During GLP-1 GI side effects with dehydration, diuretics/ACE inhibitors/ARBs may need temporary holding — agree on a plan in advance.

Don't adjust BP medication yourself

Reducing or stopping antihypertensives without your clinician can cause rebound hypertension (some drugs) or leave you under-treated. Conversely, leaving full-dose meds in place as your own BP falls can cause symptomatic low blood pressure and falls. Bring home readings and let your prescriber manage the taper.

What to do with your numbers

BP trending down, no symptoms: good — share home readings at follow-up; your clinician may start reducing medication as the trend holds.
Lightheaded, dizzy on standing, or fatigued: check your BP; if it's low, contact your clinician — your meds may need stepping down.
On a diuretic, ACE inhibitor, or ARB: ask about sick-day holds during GLP-1 GI side effects to protect against dehydration-related problems.
Already off some BP meds: keep monitoring — as weight stabilizes, your clinician can confirm you still don't need them.

Bottom line

GLP-1 and GLP-1/GIP drugs reliably lower blood pressure, and the trial evidence shows real-world reductions in antihypertensive medication use^[1]^[2]. For many people, losing weight on these drugs means they can safely come off some BP medication — a genuine win. But deprescribing is a monitored, clinician-led taper, not a self-directed stop, and the flip side (symptomatic low BP from unchanged meds) is just as important to catch. Track your readings and let your prescriber steer.

This article is educational and is not medical advice. Every claim above is sourced to a peer-reviewed trial analysis or meta-analysis indexed in PubMed, verified against the live PubMed database before publication. Never start, stop, or change blood-pressure medication without your clinician.

References

1.Kosiborod MN, Bhatta M, Davies M, Deanfield JE, Garvey WT, Khalid U, Kushner R, Rubino DM, Zeuthen N, Verma S. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes Obes Metab. 2023. PMID: 36200477.
2.Kanbay M, Copur S, Siriopol D, Yildiz AB, Berkkan M, Tuttle KR, Zoccali C. Effect of tirzepatide on blood pressure and lipids: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2023. PMID: 37700437.